Navigation Links
AACC Cautions FDA Against Over-regulating the Genetic Testing Technology Vital to Precision Medicine
Date:3/16/2015

WASHINGTON, March 16, 2015 /PRNewswire-USNewswire/ -- Today AACC sent formal comments to the Food and Drug Administration (FDA) on the agency's proposed regulation of next-generation sequencing tests. AACC appreciates FDA's efforts to seek input from the healthcare community before developing new policy in this area, but is concerned that FDA regulation of next-generation sequencing could impede the advancement of precision medicine. 

Precision medicine uses a person's unique biological makeup, including genetics, to determine which treatments that person would respond to best. Genetic tests hold the potential to predict an individual's risk of developing numerous different conditions throughout life. Having this knowledge could lead one to take a more proactive approach to his or her health, particularly with respect to chronic diseases such as cardiovascular disease and diabetes that could be prevented with basic lifestyle changes. Next-generation sequencing will enhance the application of precision medicine by making genetic testing more readily available.

After reviewing FDA's preliminary discussion paper on the topic, "Optimizing FDA's Regulatory Oversight of Next-Generation Sequencing Diagnostic Tests," AACC recommends that oversight of next-generation sequencing remain under the Clinical Laboratory Improvement Amendments (CLIA) like other laboratory developed tests. CLIA-regulated laboratories conducting next-generation sequencing testing are experienced in developing, verifying, and performing clinical tests. AACC believes that CLIA-recognized accrediting bodies and professional societies should continue to take the lead in providing oversight and guidance for next-generation sequencing testing in the absence of specific, identified problems with this approach.  

"AACC agrees with the FDA that next-generation sequencing tests offer great opportunities for advancing laboratory medicine and improving patient care, and we commend the agency's efforts to initiate a dialogue among the various organizations and professionals involved in next-generation sequencing and those affected by such testing," said AACC President Dr. David D. Koch. "We believe, however, that the current oversight mechanisms in place for next-generation sequencing are sufficient for dealing with the particular challenges this technology presents and that further FDA involvement at this time might hinder the advancement of this field." 

Read AACC's comment letter here

About AACC 
Dedicated to achieving better health through laboratory medicine, AACC brings together more than 50,000 clinical laboratory professionals, physicians, research scientists, and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking laboratory science. Since 1948, AACC has worked to advance the common interests of the field, providing programs that advance scientific collaboration, knowledge, expertise, and innovation. For more information, visit www.aacc.org

Molly Polen
AACC
Director of Communications & PR
(p) 202.420.7612
(c) 703.598.0472
mpolen@aacc.org

Logo - http://photos.prnewswire.com/prnh/20130701/PH41045LOGO


'/>"/>
SOURCE AACC
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Organovo Cautions Investors in Regards to "Short and Distort" Articles
2. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
3. Halozymes Phase 1b Clinical Trial Of PEGPH20 With Gemcitabine Indicates Positive Activity Against Pancreatic Cancer
4. ResMed Takes Action to Enforce Patents Against BMC and 3B
5. Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Invacare Corporation
6. Bernstein Liebhard LLP Announces That a Class Action Has Been Filed Against Intuitive Surgical, Inc.
7. Royalty Pharma Urges Elan Shareholders to Vote AGAINST ALL FOUR Elan Resolutions Today
8. PDL Files for Arbitration Against Genentech Based on Underpayment of Royalties
9. Consumer Watchdog: United Healthcare Sued for Discriminating Against HIV/AIDS Patients
10. The World Customs Organization (WCO) and the Institute of Research Against Counterfeit Medicines (IRACM) issue a new warning about the health and safety of African populations
11. Elan ADS Holders Decisively Vote Against Theravance And AOP Transactions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2019)... ... November 22, 2019 , ... For the third year in a ... annual USGBC Greenbuild conference and expo in addition to showcasing a test installation of ... company’s Patcraft, Shaw Contract and Shaw Floors Builder Group brands. , Shaw offered five ...
(Date:11/23/2019)... (PRWEB) , ... November 23, 2019 , ... ... -- the number of birthdays we’ve celebrated -- has also broadly served as ... age isn’t the best way to make those assessments? , Researchers at the ...
(Date:11/22/2019)... ... November 22, 2019 , ... ... at Misch International Implant Institute. Completing this three-year program enhances Dr. Hogan’s expertise ... who are seeking permanent tooth replacement solutions. The Misch International Implant Institute has ...
Breaking Medicine Technology:
(Date:12/4/2019)... , ... December 04, 2019 , ... ... Opuntia Mesocarp Extract®, provides protection from disruptions to cells and tissue and inflammation ... menace of Jet Lag, is available in a dietary supplement product called ...
(Date:12/4/2019)... NEW YORK (PRWEB) , ... December 04, 2019 ... ... a Phase I study of AZD4041 for treating tobacco use and dependence. The ... is a central nervous system (CNS) penetrant antagonist of orexin-1 (hypocretin-1) receptors that ...
(Date:11/30/2019)... Texas (PRWEB) , ... November 28, 2019 , ... As ... may be the last such holiday for one of their loved ones. For those ... them to be home for the holiday season. , Spending their final months at ...
(Date:11/27/2019)... DIEGO (PRWEB) , ... November 27, 2019 , ... ... today announced that its cloud-based platform Nucleus.io has debuted major feature sets that ... This release will be shared with the public for the first time at ...
(Date:11/24/2019)... ... November 23, 2019 , ... At the 7th annual JADPRO ... presented the second annual Mary Pazdur Award for Excellence in Advanced Practice in ... Arizona. , Dr. Pelusi, a nurse practitioner, educator, and clinical trial sub-investigator with ...
Breaking Medicine News(10 mins):